BioLab Holdings, Inc., a Phoenix-based medical manufacturer specializing in wound healing and wound care products, is pleased to announce the approval of its randomized control trial designed to evaluate the efficacy of its Membrane Wrap™ in venous leg ulcers.
The trial, known formally as „A Multi-Center, Prospective, Randomized Trail Evaluating the Efficacy of Membrane Wrap, a Human Amniotic Membrane, on Venous Leg Ulcers in an Elderly Population,“ is organized in conjunction with MCRA in Washington D.C.
Working alongside MCRA, BioLab successfully completed protocol for the trial and gained Institutional Review Board approval to move forward. Over the next two to eight weeks, agreements are being sent to the 18 vetted clinical sites that will conduct the trial and once signed, enrollment for the study will begin.
